Taurochenodeoxycholate

Taurochenodeoxycholate

SCHEMBL20204256

CC(CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@]12C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 12/20 1.00
▸ NR1H4 Q96RI1 6/20 1.00
▸ SLC10A2 Q12908 3/20 1.00
▸ ABCC4 O15439 2/20 1.00
▸ ABCB11 O95342 2/20 1.00
▸ ENPP2 Q13822 2/20 1.00
▸ PLA2G1B P04054 1/20 1.00
▸ SLC10A1 Q14973 6/20 0.89
▸ VDR P11473 1/20 0.79
▸ NR3C1 P04150 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Taurochenodeoxycholate SCHEMBL19360984 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL20261730 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL17703645 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurursodiol SCHEMBL40764 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL24001493 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL24435723 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL56780 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL24015433 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL56779 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11
Taurochenodeoxycholate SCHEMBL12917602 1.00 GPBAR1 (1.00) GPBAR1NR1H4SLC10A2ABCC4ABCB11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3350313-B1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2025-11-26 — — EP claimed
US-20210148893-A1 METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) CLAYTON PHARMACEUTICALS LLC (US) 2021-05-20 — — US claimed
EP-3423829-B1 METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) CLAYTON PHARMACEUTICALS LLC (US) 2020-10-28 — — EP claimed
US-9989519-B1 Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) Clayton Pharmaceuticals, LLC (US) 2018-06-05 — — US claimed
EP-3350313-B1 DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) 2025-11-26 — — EP disclosed
US-20210148893-A1 METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) CLAYTON PHARMACEUTICALS LLC (US) 2021-05-20 — — US disclosed
EP-3423829-B1 METHOD FOR DETERMINING IN VITRO BIOEQUIVALENCE OF A SUCRALFATE SUSPENSION SAMPLE TO A SUCRALFATE SUSPENSION REFERENCE LISTED DRUG (RLD) CLAYTON PHARMACEUTICALS LLC (US) 2020-10-28 — — EP disclosed
US-9989519-B1 Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) Clayton Pharmaceuticals, LLC (US) 2018-06-05 — — US disclosed
Send feedback